TX-SNOW-SOFTWARE
10.11.2022 15:01:39 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today announced new and enhanced capabilities to support IT leaders seeking to negotiate better contract terms, lower operating expenses and boost organizational-wide efficiencies during this period of macroeconomic uncertainty. The latest features offer a richer view of an organization’s IT investments and the impact to the business, providing new ways to optimize costs and ensure value of complex technologies like containers and cloud services. Container visibility, one of the newest innovations on the Snow Atlas platform, provides details on applications running in Kubernetes containers to identify cost savings.
“The macroeconomic environment is forcing organizations to seek a deeper understanding of how all areas of their business are performing,” said Sanjay Castelino, Chief Product and Customer Officer at Snow. “With large annual budgets devoted to IT spend, demonstrating return on investment for every technology purchase is vital for CIOs and IT teams. The latest release from Snow not only identifies how technology is used but also offers use cases to support more sustainable IT practices such as understanding the carbon footprint of devices. With IT environments more complex than ever, the intelligence Snow provides serves as the backbone for organizations seeking to get more control over IT spending and risk.”
Gaining Visibility of Container Environments
More than 70% of global organizations will use containerized applications by 2023, according to industry analysts. Widespread use of containers creates new barriers for organizations seeking to understand what is running in a container – let alone control costs.
The new container visibility feature available on Snow Atlas is designed to provide IT teams and IT asset managers (ITAM) details on what applications are running, how many containers are used in their environment, and how long containers have been running. In this release, the capability provides insights into Microsoft, Oracle and Red Hat standard containerized applications running in Kubernetes environments. Container visibility is available for Kubernetes environments running on major cloud services such as Amazon Web Services (AWS) and Microsoft Azure environments. This insight enables IT and ITAM teams to manage cost more efficiently.
Snow is inviting organizations with Kubernetes environments to use the functionality, with general availability of the capability aimed at early 2023.
Empowering ITAM to Partner with FinOps to Manage Rising Cloud Costs
To give a more complete picture of the end-to-end organizational tech stack, the latest release from Snow gives ITAM teams a spend snapshot across AWS and Azure in the terminology and views used by ITAM. With this new service – available to all Snow Atlas customers – ITAM teams have improved views of their organization’s spend profile in public cloud natively within their SAM tool. By building this feature natively within the existing SAM product, Snow makes it easier for ITAM to drive conversations about spend optimization with cloud stakeholders and FinOps teams.
For organizations with more mature cloud practices, FinOps or cloud operations practitioners, Snow Cloud Cost powered by Anodot provides greater depth of visibility, insights and analysis on public cloud spend, controls for budget management and spend allocation, detection of anomalies and recommendations for optimizing spend.
Enabling IT to Build a Sustainable Enterprise
Developing a more sustainable enterprise is a top priority for most CIOs. Snow makes it easier for IT teams to deliver on their sustainability goals. Organizations can leverage existing ITAM data, such as the laptop and desktop details, to assess their sustainability baseline. This sustainability intelligence report from Snow also includes curated information on how many certified sustainable devices exist, the spectrum of energy efficient devices and an evaluation of carbon emission reduction with on-premises to cloud shifts. The data provided by Snow enables CIOs and IT leaders to take proactive measures to actively manage and advance their sustainability initiatives.
Expanded Support to Reduce S/4HANA Migration Risks
With the end of maintenance for Business Suite 7 approaching, the migration to S/4HANA is a strategic imperative for many organizations. Snow is releasing new license intelligence, contract management and management dashboards for Snow Optimizer for SAP® Software to help offer further support with S/4HANA migrations. The new license intelligence capabilities allow organizations to easily simulate alternative license scenarios for both usage and authorization-based licensing, helping them decide on the most efficient and cost-effective migration strategy. In addition, new functionality allows for more transparent and secure management of an organization’s SAP environment by providing insight into license metrics and enhanced controls over contract management.
These new and enhanced capabilities follow several notable product milestones for Snow this year, including a new host of capabilities for Snow Atlas, a new partnership with Anodot to transform cloud cost management, verification on Oracle Database and Database Options and new enhancements for Snow Commander.
For more information or to request a demo, please visit www.snowsoftware.com.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005344/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom